Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 600 shares at $13.07 ($8K) on 2022-08-17, disclosed to the SEC on 2022-08-18.
Scheduled sale ($8k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.00 | 200 | $3K | 33.3% |
| 2 | $13.07 | 200 | $3K | 33.5% |
| 3 | $13.00 | 200 | $3K | 33.3% |
| Total | $13.02 avg | 600 | $8K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |